Walter Greenblatt & Associates | Bridging the Gap Between Science & Investment

from INCEPTION to EXIT

INCEPTION

WALTER GREENBLATT & ASSOC.
helps scientists raise the captial they need to create proof-of-concepts

DEVELOPMENT

WALTER GREENBLATT & ASSOC.
helps scientists bring their product to the market

GROWTH

WALTER GREENBLATT & ASSOC.
helps raise capital necessary for company to reach the next stage of development

EXIT

WALTER GREENBLATT & ASSOC.
helps biotech owners plan exit strategies that yield “Maximum Value”

Summer 2017
Illuminare Biotechnologies closed a $2.3M Series A round

July 2017
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data
Read the full press release... Spring 2017
RenalSense raises $2.2 million from angel investors

2017
GPB Scientific raises $1.0 million from angel investors
2016-2017
ILiAD Biotechnologies raises $2.6 million from angel investors

Spring 2016
GPB Scientific raises $1.0 million from angel investors

Spring 2016
ILiAD Biotechnologies raises $1.0 million from angel investors

Fall 2015
RenalSense closes $3.6 million Series A round.

Fall 2015
Iliad Biotechnologies closes $3.7 million financing round.

Fall 2015
GPB Scientific closes $1.6 million Series A round from angel investors.

June/Oct. 2013
CytoSorbents raises $0.8 million from angel investors.
November 2013
Callidus Biopharma acquired by Amicus Therapeutics (NASDAQ-FOLD) for $15 million upfront payment with potential milestone payments totaling $115 million.

Click here to read the full press release...
November 2013
Hygeia Therapeutics acquired by Stratus Media Group (OTCBB-SMDI).

Read the full press release... March 2013
Callidus BioPharma Announces Close of $4.6 million from Strategic Investors & Angels.


Read the full press release... January 2012
Callidus Biopharma receives $1.6 million from Angel and strategic investors.
August 2011
Lerner Medical Devices receives $1.0 million from Angel investors.

2009-10
Lerner Medical receives $4.5 million from Angel investors.

Dec. 2007
Lerner Medical receives $3.3 million from Angel investors.
March 2011
Core Essence Orthopaedics receives $5.2 million Series B from institutional VC investors.

October 2010
Core Essence Orthopaedics receives a $2.9 million Series A from Angel investors.
July 2011
Shire Pharmaceuticals purchases Advanced BioHealing for $750 million in cash.
November 2009
Lerner Medical Devices receives 510(k) clearance from the FDA for Levia®.
June 2008
MedAvante closes on $20 million Institutional round led by Goldman Sachs and Trevi Health Ventures; Walter Greenblatt & Associates, exclusive financial advisor to MedAvante.
August 2007
WuXi PharmaTech (NYSE: WX), IPOs on the New York Stock Exchange with a $1 billion market cap.
More